200 300 400 500 600 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg -400 -300 -200 -100 0 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg APEX KSI-101 in MESI – Meaningful anatomical gains are rapidly achieved, with all dose levels achieving dryness OCT CST levels as early as Week 4 74 Microns Microns Mean Change in OCT CST in patients completing Week 12 Observed OCT CST over time in patients completing Week 12 2.5 mg 9 9 9 9 9 5 mg 8 8 8 8 8 10 mg 10 10 10 10 10 N values N values Weeks Weeks 2.5 mg 9 9 9 9 9 5 mg 8 8 8 8 8 10 mg 10 10 10 10 10 Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that completed the Week 12 visit by the cutoff date of 14-Jul-25 and meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion) Dryness